• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

New Opportunities

Quote
anonymous said:
Bitter party of 1 who got passed over for RBM position, your table is ready.
Click to expand...

I’m not so sure about that. I know a couple of people who interviewed and came back and turned down the offer. I also know a few who accepted and are very excited. It’s going to be a challenge but the comp is damn good. I hope they succeed.
 




anonymous said:
I’m not so sure about that. I know a couple of people who interviewed and came back and turned down the offer. I also know a few who accepted and are very excited. It’s going to be a challenge but the comp is damn good. I hope they succeed.
Click to expand...
I’ll take good comp any day. Can’t control how good or bad a drug is, all you can do is work your territory. Better comp makes a bad drug easier to deal with. In fact, if it’s going to be tough, better pay well if you intend to have reps.
 




anonymous said:
I’ll take good comp any day. Can’t control how good or bad a drug is, all you can do is work your territory. Better comp makes a bad drug easier to deal with. In fact, if it’s going to be tough, better pay well if you intend to have reps.
Click to expand...

agreed all these new cocktail drugs will have their challenges. That’s why they pay the big bucks. Reps jump jobs often now. If things don’t workout jump ship.
 
















They sell culture as their #1 talking point. I spent two years there before everyone was laid off. The culture was great but Sr Leadership had no clue on how to launch, secure coverage with managed care, etc. The drug in the oral form looks good but if not priced right and coverage is not good it will be a shit show. Good luck to all
 




anonymous said:
They sell culture as their #1 talking point. I spent two years there before everyone was laid off. The culture was great but Sr Leadership had no clue on how to launch, secure coverage with managed care, etc. The drug in the oral form looks good but if not priced right and coverage is not good it will be a shit show. Good luck to all
Click to expand...
Shut the fuck up
 








You STFU. Check back in a year and let us know how it goes when your sales and market acceptance are below expectations. Trust me all the free swag and culture bullshit won’t save you when your launch flops
 
























Wow! Such HOSTILITY here, why? All these pharma jobs are a joke, MD's can't be bothered, fat ladies in the office like us though, free lunch & snacks! This company will be NO different than any other of these crap holes, people just want to know "simple info": are they hiring, who's the hirer......no need for nasty, foul language. We are all in this sewer together, get along. Nowhatibesayin?
 




anonymous said:
From very good inside sources, the plan is to charge an insane amount for this drug. Numerous step-edits expected as best case scenario. No one will be covering and Sr Leadership not willing to discount for access. This is going to be another Sage nightmare! Charm you with the "culture" and allow you to fail in the field. Get prepared for heavy metrics (just look at leadership and their background). You can call this "specialty" to gain interest from good candidates however this will be highly a primary care type position for those in the field. Not enough psychiatry to drive demand they expect with the bait and switch coming to focus on where patients are being seen by providers (Primary Care). Good luck if you are in a difficult access area as metrics and performance wont be an excuse or consideration for goal setting.
Unrealistic expectations for an average clinical effect at a premium price with no access = Dead On Arrival. This will be another Zulresso experience for those that lived it, only with more greed and leadership that is lacking.
Shit flows downhill and there is a huge pile at the top ready to come down. Be very aware if interviewing and ask the right questions. They will bribe you with stock options and the stock hasnt moved in preparation for this drug. It is filled with doubt in the medical community due to more negatively around it than positivity. Just look at market reaction to any Sage news: always goes down!
How do I know? Have several connections with Sage, talked to clinicians about their lack of desire for this drug (which I have great connections due to many years calling on psychiatry). Finally, I passed on a decent offer to lead a regional team knowing bonus are going to be few and far between (maybe AZ, TX & FL have a chance). This is not the greener grass! My advice based off of internal Sage & high-profile psych conversations with those in the "know". You can take or ignore what I am writing, but facts are facts.
Click to expand...

Very insightful response. I was recently notified on LinedIn that a former colleague of mine was recently hired here as a RSD somewhere in SoCal. MGraham is the epitome of a primary care mentality manager. His reputation precedes him - to any reps interviewing with that disaster… you’ve been warned. Get ready for Lazy Manager 101. Warning signs: he’ll talk up his “LTC experience at Shionogi (he was actually a Syneos contractor). Then he’ll talk about the “Lexapro days” when talking about contracting wins. Good luck expecting him to have your back once numbers don’t come in his favor. In summation: Sage picked up a pharma retread with no redeeming value. Will be watching vigilantly to see if there are any horror stories that pop up once he’s started his official reign of disappointment
 








anonymous said:
Very insightful response. I was recently notified on LinedIn that a former colleague of mine was recently hired here as a RSD somewhere in SoCal. MGraham is the epitome of a primary care mentality manager. His reputation precedes him - to any reps interviewing with that disaster… you’ve been warned. Get ready for Lazy Manager 101. Warning signs: he’ll talk up his “LTC experience at Shionogi (he was actually a Syneos contractor). Then he’ll talk about the “Lexapro days” when talking about contracting wins. Good luck expecting him to have your back once numbers don’t come in his favor. In summation: Sage picked up a pharma retread with no redeeming value. Will be watching vigilantly to see if there are any horror stories that pop up once he’s started his official reign of disappointment
Click to expand...

Did they hire MGraham for Women’s Health or Neuro? I can’t believe they hired him at all. Total douche. I guess Sage pulled a bunch of Intra-Cellular people without even bothering to do any BI’s to investigate their lack of talent and severe lack of ability to lead. I blame it on the hiring managers. Weak.
Good luck Sage. He won’t make his numbers.
 




anonymous said:
Did they hire MGraham for Women’s Health or Neuro? I can’t believe they hired him at all. Total douche. I guess Sage pulled a bunch of Intra-Cellular people without even bothering to do any BI’s to investigate their lack of talent and severe lack of ability to lead. I blame it on the hiring managers. Weak.
Good luck Sage. He won’t make his numbers.
Click to expand...
Well, the first go-round was Novo Nordisk retreads that got hired despite their lack of documented performance or without any due diligence. Many of those hold-overs are still here, so why would we expect any different?
 




Top Bottom
Back
Quote